Sanuwave Health, Inc. Provides Earnings Guidance for the First Quarter 2024
April 10, 2024 at 08:30 am EDT
Share
SANUWAVE Health, Inc. provided earnings guidance for the First Quarter 2024. For the period, the company expects revenues to be in the range of $5.7 million to $5.9 million, an increase of 51% to 56% over First Quarter 2023 and consistent with the high end of the range of guidance given in the Company?s Fourth Quarter 2023 earnings release from March 22, 2024.
Sanuwave Health, Inc. is an ultrasound and shock wave technology company. The Company is a provider of Food and Drug Administration (FDA)-approved wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. The Company applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and others. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing from within. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression (PACE) technology to converge at precise selected targets to produce an extremely short duration compression burst.
SANUWAVE HEALTH, INC. 
